Cargando…
Targeting Trimethylamine N-Oxide: A New Therapeutic Strategy for Alleviating Atherosclerosis
Atherosclerosis (AS) is one of the most common cardiovascular diseases (CVDs), and there is currently no effective drug to reverse its pathogenesis. Trimethylamine N-oxide (TMAO) is a metabolite of the gut flora with the potential to act as a new risk factor for CVD. Many studies have shown that TMA...
Autores principales: | Jing, Lele, Zhang, Honghong, Xiang, Qiannan, Shen, Liang, Guo, Xiaoxia, Zhai, Changlin, Hu, Huilin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9235870/ https://www.ncbi.nlm.nih.gov/pubmed/35770223 http://dx.doi.org/10.3389/fcvm.2022.864600 |
Ejemplares similares
-
Intestinal Flora Metabolite Trimethylamine Oxide Is Inextricably Linked to Coronary Heart Disease
por: Zhang, Honghong, et al.
Publicado: (2022) -
Gut Metabolite Trimethylamine-N-Oxide in Atherosclerosis: From Mechanism to Therapy
por: Wang, BingYu, et al.
Publicado: (2021) -
The Link Between Ferroptosis and Cardiovascular Diseases: A Novel Target for Treatment
por: Hu, Huilin, et al.
Publicado: (2021) -
Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value
por: Li, Xingxing, et al.
Publicado: (2022) -
Trimethyllysine, a trimethylamine N-oxide precursor, predicts the presence, severity, and prognosis of heart failure
por: Zong, Xiao, et al.
Publicado: (2022)